Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | IGF2R | P11717 | 4/20 | 0.43 |
| ▸ | SELL | P14151 | 6/20 | 0.43 |
| ▸ | SELP | P16109 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618346 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL17188539 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL15618340 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL15618301 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL15618428 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL15618302 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL15618429 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL5689541 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL15870699 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP | |
| SCHEMBL20090271 | 1.00 | GBA1 (0.55) | GBA1MAPK1IGF2RSELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741311-B2 | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing | MOUSA SHAKER | 2010-06-22 | — | — | US | disclosed |
| US-20060147415-A1 | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing | MOUSA SHAKER | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060147415-A1 | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing | ALG1, SDC2, SDC1 | GBA1 288/4885MAPK1 3883/4885IGF2R 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.